Purpose: To compare the effects of high- (Group 1) and low-dose (Group 2) isotretinoin treatments for acne vulgaris on lacrimal functions and other ocular complications.

Methods: Twenty-six patients receiving high-dose (>0.5 mg/kg per day) systemic isotretinoin treatment and 25 patients treated with low-dose systemic isotretinoin (<0.5 mg/kg per day) underwent complete ophthalmologic assessment of both eyes before treatment, at days 45 and 90 of treatment, and 1 month after the completion of treatment, together with a microbiologic evaluation of conjunctival flora, tear film break-up time (BUT), and anesthetized Schirmer test of the right eye of each patient.

Results: When the results of the anesthetized Schirmer test for Groups 1 and 2 were compared (pretreatment, days 45 and 90 of treatment, and 1 month after treatment), there was no statistically significant difference between the groups (p > 0.05). Although BUT did not differ significantly between the two groups before treatment (p >0.05), there was a statistically significant decrease in BUT in Group 1 when compared with Group 2 at days 45 and 90 of treatment (p <0.05). One month after the completion of treatment, there was no difference in BUT between the two groups (p >0.05). No difference in Staphylococcus aureus colonization was detected between the two groups at days 45 and 90 of treatment (p >0.05).

Conclusions: During systemic isotretinoin treatment, eye dryness was related to the dose used, at least during the period of treatment. Conversely, the rate of conjunctival S aureus colonization was unrelated to the dose of isotretinoin.

Download full-text PDF

Source
http://dx.doi.org/10.1177/112067210901900204DOI Listing

Publication Analysis

Top Keywords

systemic isotretinoin
16
isotretinoin treatment
8
days treatment
8
aureus colonization
8
isotretinoin
6
treatment
6
comparison dose-related
4
dose-related ocular
4
ocular side
4
side effects
4

Similar Publications

Article Synopsis
  • This review analyzes the effects of oral retinoids like isotretinoin on wound healing across different surgical fields.
  • It raises concerns about the common practice of stopping these medications before surgery, suggesting it's not always necessary based on current research.
  • The article calls for personalized decisions regarding retinoid use before surgery and highlights the importance of collaboration between dermatologists and surgeons for better perioperative care.
View Article and Find Full Text PDF
Article Synopsis
  • This study examines the effects of oral isotretinoin on eye health in patients with acne vulgaris, highlighting issues like dryness and discomfort.
  • A survey of 489 participants showed a high prevalence of ocular symptoms linked to isotretinoin use, with notable findings including a majority experiencing soreness and blurred vision.
  • Key risk factors for worsening eye symptoms included contact lens use and higher isotretinoin dosages, suggesting the need for careful monitoring and preventive measures for patients at risk.
View Article and Find Full Text PDF

Isotretinoin (13-cis-retinoic acid) is a well-established systemic treatment for moderate to severe acne vulgaris, renowned for its ability to target multiple contributors to acne pathogenesis. However, its therapeutic potential extends beyond conventional acne management. This case report highlights its efficacy in treating recalcitrant pustular dermatosis, a condition that proved resistant to standard therapies and posed significant diagnostic challenges.

View Article and Find Full Text PDF

Serum Catestatin Levels in Patients with Acne Vulgaris: Single-Center Prospective Study.

Skin Appendage Disord

December 2024

Department of Dermatology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.

Introduction: Recent studies showed that antimicrobial peptides have an essential role in the pathogenesis of acne vulgaris. This study aims to investigate serum catestatin levels in acne vulgaris patients and focuses on the change in serum levels after systemic isotretinoin therapy.

Methods: This prospective study includes 101 acne vulgaris patients and 28 healthy controls.

View Article and Find Full Text PDF

Epidermal growth factor receptor inhibitors (EGFRi) are approved for treating various cancers. Given that EGFR signaling is crucial for normal skin growth and repair, inhibiting this pathway can disrupt skin homeostasis and integrity. Although generally well tolerated, molecularly targeted therapies can lead to skin-related adverse effects that significantly impact patients' quality of life, often resulting in treatment interruptions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!